Global Green Inc. has signed an agreement with Merial, the animal health division of Sanofi, to conduct an internal evaluation of Global Green's patented Salmogenics Salmonella vaccine technology. Salmogenics is the only patented Salmonella vaccine injected into the egg before the chick is hatched.
At the conclusion of the evaluation, Merial has the first option to enter into a license agreement with Global Green for the manufacturing, distribution and sale of the vaccine. Details of the evaluation agreement are confidential.
The aim of the Salmogenics vaccine is to improve the immune system, health and welfare of broiler chickens, and to provide a healthier source of protein for humans in a more cost-effective manner. Salmogenics testing has demonstrated a stronger immune system against Salmonella as well as increased weight gain and reduced mortality in poultry, according to a Global Green press release. By using Salmogenics, broiler operators could also lessen the need for use of antibiotics.
"This agreement with a world leader in the animal health sector, such as Merial, further confirms the significance of our patented Salmogenics vaccine technology. Our goal at Global Green is to produce vaccines that improve early immunity in chickens and other animals, providing a safer and more cost-effective food source. Global Green's approach to animal health is to produce innovative, environmentally-safe products and solutions which enhance the health, well-being and performance of animals," said Dr. Mehran Ghazyini, chairman and CEO of Global Green Inc.
